EA201790080A1 - Кристаллический о-метилоксим (3z,5s)-5-(гидроксиметил)-1-[(2'-метил-1,1'-бифенил-4-ил)карбонил]пирролидин-3-он, полезный в способах лечения состояний, связанных с активностью ot-r - Google Patents

Кристаллический о-метилоксим (3z,5s)-5-(гидроксиметил)-1-[(2'-метил-1,1'-бифенил-4-ил)карбонил]пирролидин-3-он, полезный в способах лечения состояний, связанных с активностью ot-r

Info

Publication number
EA201790080A1
EA201790080A1 EA201790080A EA201790080A EA201790080A1 EA 201790080 A1 EA201790080 A1 EA 201790080A1 EA 201790080 A EA201790080 A EA 201790080A EA 201790080 A EA201790080 A EA 201790080A EA 201790080 A1 EA201790080 A1 EA 201790080A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
crystalline
pyrrolidin
biphenyl
hydroxymethyl
Prior art date
Application number
EA201790080A
Other languages
English (en)
Other versions
EA031353B1 (ru
Inventor
Андрэ Шолле
Original Assignee
Обсева Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Обсева Са filed Critical Обсева Са
Publication of EA201790080A1 publication Critical patent/EA201790080A1/ru
Publication of EA031353B1 publication Critical patent/EA031353B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

В настоящем документе описан кристаллический О-метилоксим (3Z,5S)-5-(гидроксиметил)-1-[(2'-метил-1,1'-бифенил-4-ил)карбонил]пирролидин-3-он. Также описана фармацевтическая композиция, содержащая указанное кристаллическое соединение, а также способы лечения состояний, связанных с активностью OT-R, таких как преждевременные роды, и способы увеличения частоты имплантации эмбриона у млекопитающего, подвергающегося переносу эмбриона, включающие введение указанного кристаллического соединения.
EA201790080A 2014-07-02 2015-06-10 Кристаллический о-метилоксим (3z,5s)-5-(гидроксиметил)-1-[(2'-метил-1,1'-бифенил-4-ил)карбонил]пирролидин-3-он, полезный в способах лечения состояний, связанных с активностью ot-r EA031353B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462020076P 2014-07-02 2014-07-02
PCT/EP2015/062881 WO2016000920A1 (en) 2014-07-02 2015-06-10 Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity

Publications (2)

Publication Number Publication Date
EA201790080A1 true EA201790080A1 (ru) 2017-06-30
EA031353B1 EA031353B1 (ru) 2018-12-28

Family

ID=53434312

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201790080A EA031353B1 (ru) 2014-07-02 2015-06-10 Кристаллический о-метилоксим (3z,5s)-5-(гидроксиметил)-1-[(2'-метил-1,1'-бифенил-4-ил)карбонил]пирролидин-3-он, полезный в способах лечения состояний, связанных с активностью ot-r
EA201891873A EA201891873A1 (ru) 2014-07-02 2015-06-10 Кристаллический о-метилоксим (3z,5s)-5-(гидроксиметил)-1-[(2'-метил-1,1'-бифенил-4-ил)карбонил]пирролидин-3-он, полезный в способах лечения состояний, связанных с активностью ot-r

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201891873A EA201891873A1 (ru) 2014-07-02 2015-06-10 Кристаллический о-метилоксим (3z,5s)-5-(гидроксиметил)-1-[(2'-метил-1,1'-бифенил-4-ил)карбонил]пирролидин-3-он, полезный в способах лечения состояний, связанных с активностью ot-r

Country Status (13)

Country Link
US (2) US9718772B2 (ru)
EP (2) EP3753921A1 (ru)
JP (3) JP2017519015A (ru)
KR (1) KR102470283B1 (ru)
CN (3) CN114105850A (ru)
AU (1) AU2015283133B2 (ru)
CA (1) CA2953722C (ru)
EA (2) EA031353B1 (ru)
ES (1) ES2774789T3 (ru)
IL (1) IL249652B (ru)
MX (1) MX371068B (ru)
UA (1) UA122210C2 (ru)
WO (1) WO2016000920A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
CA2953722C (en) 2014-07-02 2022-09-13 ObsEva SA Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime, and methods of using the same
JP6933322B2 (ja) 2016-01-04 2021-09-08 メルク セローノ エス．エー． ヒドロキシプロピルチアゾリジンカルボキサミド誘導体のｌ−バリネート及びその塩形態、結晶多形
CA3031252A1 (en) * 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
WO2021043726A1 (en) 2019-09-03 2021-03-11 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
JP7083793B2 (ja) * 2019-09-10 2022-06-13 Ｊｆｅケミカル株式会社 パラターフェニルテトラカルボン酸およびパラターフェニルテトラカルボン酸二無水物の製造方法
US20230102503A1 (en) 2020-02-10 2023-03-30 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU120988A (en) 1988-06-23 1990-06-30 Lek Tovarna Farmacevtskih Process for preparing new dispersion pills of cimetidine
YU183988A (en) 1988-09-30 1990-08-31 Lek Tovarna Farmacevtskih Process for preparing dispersion pills of dihydroergotoxine
JP2927532B2 (ja) 1989-11-09 1999-07-28 塩野義製薬株式会社 含窒素異項環オキシーフェノキシ酢酸誘導体およびその除草剤としての用途
US5889001A (en) 1993-07-29 1999-03-30 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
JP3534903B2 (ja) 1995-06-09 2004-06-07 鐘淵化学工業株式会社 １−［３−クロロ−（２ｓ）−メチルプロピオニル］−ピロリジン−（２ｓ）−カルボン酸の製造方法
GB9603699D0 (en) 1996-02-21 1996-04-17 Boots Co Plc Therapeutic composition
US6696484B2 (en) 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
SK285706B6 (sk) 1999-12-09 2007-06-07 Reckitt Benckiser Healthcare (Uk) Limited Lisovaná tabletová kompozícia, spôsob jej prípravy a jej použitie
EP1268418B1 (en) 2000-03-27 2006-06-14 Applied Research Systems ARS Holding N.V. Pharmaceutically active pyrrolidine derivatives as bax inhibitors
AU5620901A (en) 2000-03-27 2001-10-08 Applied Research Systems Pharmaceutically active pyrrolidine derivatives as bax inhibitors
TW536751B (en) 2000-07-14 2003-06-11 Nitto Denko Corp Cleaning sheet, conveying member using the same, and substrate processing equipment cleaning method using them
EP1390347B1 (en) 2001-03-20 2008-05-07 Laboratoires Serono SA Pyrrolidine ester derivatives with oxytocin modulating activity
KR200245627Y1 (ko) * 2001-05-15 2001-10-15 김병두 전기 가열부재가 부착된 냄비
SK15552003A3 (sk) 2001-06-18 2004-05-04 Applied Research Systems Ars Holding N. V. Oxadiazolové a tiadiazolové deriváty pyrolidínu, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
JP2003192582A (ja) 2001-12-12 2003-07-09 Merck Patent Gmbh ナプロキセンナトリウムを含む速放性錠剤
UA78058C2 (en) 2002-07-05 2007-02-15 Applied Research Systems Pyrrolidine derivative as oxitocin antagonists
JP4773335B2 (ja) * 2003-02-27 2011-09-14 メルク セローノ ソシエテ アノニム オキシトシンアンタゴニストとしてのピロリジン誘導体
KR20060124775A (ko) 2004-02-26 2006-12-05 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 피롤리딘 옥심의 제조방법
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
RU2385735C2 (ru) 2005-05-10 2010-04-10 Ферринг Интернэшнл Сентер С.А. Применение антагонистов окситоцина при вспомогательной репродукции
JP2008189732A (ja) 2007-02-01 2008-08-21 Fujifilm Corp セルロースアシレート組成物、セルロースアシレートフィルム、光学補償シート、偏光板および液晶表示装置
PL2572705T3 (pl) 2007-10-01 2018-01-31 Lesvi Laboratorios Sl Tabletki ulegające rozpadowi w jamie ustnej
US9201077B2 (en) 2009-07-27 2015-12-01 Colorado State University Research Foundation Direct enzyme immunoassay for measurement of serum progesterone levels
EP2922475A1 (en) 2012-11-26 2015-09-30 Ferring BV Method and system for diagnosing uterine contraction levels using image analysis
EP2845850A1 (en) * 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) * 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
CA2953722C (en) 2014-07-02 2022-09-13 ObsEva SA Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime, and methods of using the same
ES2716862T3 (es) 2014-12-22 2019-06-17 Ferring Bv Terapia con antagonistas del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida

Also Published As

Publication number Publication date
CA2953722A1 (en) 2016-01-07
US9718772B2 (en) 2017-08-01
WO2016000920A1 (en) 2016-01-07
KR102470283B1 (ko) 2022-11-23
EP3164384B1 (en) 2019-12-04
EP3753921A1 (en) 2020-12-23
CN106795110A (zh) 2017-05-31
AU2015283133B2 (en) 2019-05-16
JP2021038236A (ja) 2021-03-11
IL249652A0 (en) 2017-02-28
MX2016016751A (es) 2017-08-08
KR20170023961A (ko) 2017-03-06
EP3164384A1 (en) 2017-05-10
CA2953722C (en) 2022-09-13
US20170320822A1 (en) 2017-11-09
US10752583B2 (en) 2020-08-25
MX371068B (es) 2020-01-15
JP2023018037A (ja) 2023-02-07
CN114105851A (zh) 2022-03-01
EA201891873A1 (ru) 2019-04-30
ES2774789T3 (es) 2020-07-22
UA122210C2 (uk) 2020-10-12
AU2015283133A1 (en) 2017-02-16
JP2017519015A (ja) 2017-07-13
IL249652B (en) 2021-09-30
CN114105850A (zh) 2022-03-01
EA031353B1 (ru) 2018-12-28
US20160002160A1 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
EA201891873A1 (ru) Кристаллический о-метилоксим (3z,5s)-5-(гидроксиметил)-1-[(2'-метил-1,1'-бифенил-4-ил)карбонил]пирролидин-3-он, полезный в способах лечения состояний, связанных с активностью ot-r
EA201800367A1 (ru) Способы лечения болезни хантингтона
MX2020004894A (es) Composiciones que comprenden un inhibidor de demetilasa-1 especifico de lisina.
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
EA201790528A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
EA201790384A1 (ru) Полиморфы селинексора
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
BR112015022197A2 (pt) tratamento de cataplexia
MX2019003598A (es) Formulaciones orales de derivados de pirrolidina.
EA201590748A1 (ru) Противовирусные соединения против rsv
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
EA201790088A1 (ru) Ингибиторы syk
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201591512A1 (ru) Борсодержащие молекулы, способы и составы
CO2018005983A2 (es) Compuestos de isoindol
CY1121063T1 (el) Αναστολεις της συνθασης της αλδοστερονης
EA201790905A1 (ru) Способ лечения состояний, связанных с рецептором pgi2
WO2016094899A3 (en) Treatment of hmgb1-mediated inflammation
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
MX2022014763A (es) Composiciones de grapiprant y metodos para usar las mismas.
EA201991373A1 (ru) МОДУЛЯТОРЫ ROR ГАММА (RORγ)
EA202090164A1 (ru) Изотретиноиновые перорально-слизистые композиции и способы их применения
MD20180049A2 (ru) Фармацевтическая композиция